Overview Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects Status: Recruiting Trial end date: 2022-12-01 Target enrollment: Participant gender: Summary This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH Phase: Phase 2 Details Lead Sponsor: Hanmi Pharmaceutical Company Limited